Savale Laurent, Maitre Bernard, Bachir Dora, Galactéros Frédéric, Simonneau Gerald, Parent Florence
Université Paris-Sud, faculté de médecine, 94276 Kremlin-Bicêtre, France.
Presse Med. 2013 Mar;42(3):338-46. doi: 10.1016/j.lpm.2012.04.021. Epub 2012 Jun 27.
Recent hemodynamic studies performed in large cohorts of adult patients with sickle cell disease have established the prevalence of pulmonary hypertension in this disease about 6 to 10%. Over half of these correspond to postcapillary pulmonary hypertension. Precapilliary arterial pulmonary hypertension seems to be a relatively infrequent complication of the disease. It is characterized by a different hemodynamic profile of idiopathic PAH with lower levels of pulmonary pressures and pulmonary vascular resistance. However, pulmonary vascular disease appears to have a significant impact on the functional status and vital prognosis of patients with sickle cell disease. The predictive value of echocardiography to detect pulmonary hypertension in this population is low (25-32%) when the threshold of tricuspid regurgitation velocity of 2.5m/s is used. At present, no specific treatments for pulmonary arterial hypertension is currently approved for the treatment of PAH associated with sickle cell disease due to lack of data in this specific population.
近期在大量成年镰状细胞病患者队列中进行的血流动力学研究表明,该疾病中肺动脉高压的患病率约为6%至10%。其中超过一半为毛细血管后肺动脉高压。毛细血管前动脉性肺动脉高压似乎是该疾病相对少见的并发症。其特征是与特发性肺动脉高压不同的血流动力学特征,肺动脉压力和肺血管阻力水平较低。然而,肺血管疾病似乎对镰状细胞病患者的功能状态和生命预后有重大影响。当使用三尖瓣反流速度2.5m/s的阈值时,超声心动图检测该人群中肺动脉高压的预测价值较低(25%-32%)。目前,由于该特定人群缺乏数据,尚无专门批准用于治疗与镰状细胞病相关的肺动脉高压的肺动脉高压特异性治疗方法。